论文部分内容阅读
目的分析早期2型糖尿病肾病患者血清载脂蛋白CIII(apoCIII)水平变化,探讨瑞舒伐他汀对其影响。方法 120例2型糖尿病患者分为单纯2型糖尿病组和早期糖尿病肾病组,每组60例,早期糖尿病肾病组又分为瑞舒伐他汀治疗组和未治疗组,每组30例,治疗组给予瑞舒伐他汀10 mg,每日1次口服,共24周,分别于治疗前及治疗24周时检测所有患者的血清空腹血糖(FBG)、糖化血红蛋白(HbA1c)、三酰甘油(TG)、总胆固醇(TC)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)、极低密度脂蛋白(VLDL)、apoCIII水平和24 h尿微量清蛋白(MAU)水平并进行比较。结果与单纯2型糖尿病患者比较,早期糖尿病肾病患者血清apoCIII水平明显升高,差异有统计学意义(P<0.01)。早期糖尿病肾病瑞舒伐他汀治疗组经瑞舒伐他汀治疗后,TG、TC、LDL、VLDL、apoCIII及MAU水平下降,HDL水平升高,差异有统计学意义(P<0.05)。结论早期糖尿病肾病患者血清apoCIII水平明显升高,瑞舒伐他汀治疗可以改善其水平异常,有利于降低MAU。
Objective To analyze the change of serum apolipoprotein C (apoCIII) level in patients with early type 2 diabetic nephropathy and to investigate the effect of rosuvastatin on it. Methods 120 patients with type 2 diabetes mellitus were divided into simple type 2 diabetes mellitus and early diabetic nephropathy group, 60 cases in each group. The early stage diabetic nephropathy group was divided into rosuvastatin treatment group and untreated group, 30 cases in each group. The treatment group The patients were given rosuvastatin 10 mg orally once a day for 24 weeks. The levels of fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c) and triglyceride (TG) were measured in all patients before and 24 weeks after treatment. , Total cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL), very low density lipoprotein (VLDL), apoCIII and 24 h urinary microalbumin (MAU) Results Compared with patients with type 2 diabetes, serum apoCIII levels were significantly increased in patients with early diabetic nephropathy, the difference was statistically significant (P <0.01). After treatment with rosuvastatin, the levels of TG, TC, LDL, VLDL, apoCIII and MAU decreased and HDL increased in rosuvastatin group with early diabetic nephropathy. The difference was statistically significant (P <0.05). Conclusion Serum apoCIII levels are significantly elevated in patients with early diabetic nephropathy, and rosuvastatin treatment can improve its abnormal levels and reduce MAU.